Skip to Main Content

Four years after it was founded, Kymera Therapeutics said Thursday that it has now raised more than a quarter-billion dollars from investors keen on its potential approach to treat a range of diseases, including blood cancers.

The Cambridge, Mass., biotech shared the total after announcing that it had closed a third round of venture capital fundraising that totaled $102 million.The privately held startup plans to begin clinical trials of at least three drugs by next year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!